Skip to content

Further than NASH: NASH & Wider Fibrosis Seminar - Seminar A

Next Steps: Uptake of Drugs to Market Seminar - Seminar B

Overlap and relationships across organ-specific pathological fibrosis, as well as lessons learned from other fibrotic disease clinical drug development and regulatory intelligence.

Chaired by: Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer

 

9.00 Opening Remarks
Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer

 

9.15 The Importance of Epigenetic Changes in the Pathogenesis of NASH & Fibrosis

Glenn Rosen, Vice President, Preclinical Translational Sciences & Small Molecules, Coherus
Biosciences

 

9.45 Fibrosis & Inflammation: Approaches for Targeting

Rugmani Padmanabhan Iyer, Senior Scientist – Cardiovascular, Inflammation & Fibrosis,
Merck

 

11.00 Keeping up with the Joneses: What Can we Learn From Pulmonary & Cardiac Fibrosis?

Lee Borthwick, Fibrosis Biology Lecturer, Newcastle University

 

1.00 Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis

Rusty Montgomery, Director, Research, Miragen Therapeutics

 

1.30 CORMs: A Single NASH Therapeutic Treating Inflammation, Fibrosis & Metabolic
Stress

Jeffrey Wager, Chairman & Chief Executive Officer, Proterris

 

2.00 Lessons Learned from Antifibrotic Trials in NASH & Where do we go From Here?

Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

 

2.30 Concluding Panel Discussion: Challenges in Anti-Fibrotic Drug Development;
Why a Paradigm Shift is Needed

Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer
Glenn Rosen, Vice President – Preclinical Translational Sciences & Small Molecules,
Coherus Biosciences
Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

 

 

Understanding key considerations from pharma and payers, & evaluating consequences of change to market opportunity and access for NASH

Chaired by: Yasmeen Rahimi, Co-Head of Biotechnology Research, Managing Director, Senior Research Analyst, Roth Capital Partners

 

9.00 Opening Remarks
Chaired by: Yasmeen Rahimi, Co-Head of Biotechnology Research, Managing Director,
Senior Research Analyst, Roth Capital Partners

 

9.15 Consideration & Decision Making Process of Payers for NASH Including Opinions
on Surrogate Endpoints & the Need to Biopsy or Not

Derek Achila, Director & Senior Analyst – Biotechnology, Stifel Nicolaus

 

9.45 Potential Impact & Value of NASH Therapeutics

Jagpreet Chhatwal, Assistant Professor, Harvard Medical School

 

11.00 Panel Discussion: How do we Bring Strategies to a Wider Population?

Derek Achila, Director & Senior Analyst – Biotechnology, Stifel Nicolaus

Jagpreet Chhatwal, Assistant Professor, Harvard Medical School

Yasmeen Rahimi, Co-Head of Biotechnology Research Managing Director, Senior
Research Analyst, Roth Capital Partners

 

1.00 NASH Market in China

Ankang Li, Chief Financial Officer, Terns Pharmaceuticals

 

1.30 - 2.30 Payer's Roundtable Discussions

1.30-1.45 Introduction to Topics
1.45 - 2.15 Roundtable Discussion
2.15-2.30 Feedback Panel: Sharing insights from across tables and topics

 

2.00 Lessons Learned from Antifibrotic Trials in NASH & Where do we go From Here?

Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

 

2.30 Concluding Panel Discussion: Challenges in Anti-Fibrotic Drug Development;
Why a Paradigm Shift is Needed

Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer
Glenn Rosen, Vice President – Preclinical Translational Sciences & Small Molecules,
Coherus Biosciences
Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

For all details on each session, please download the full event guide.